The prize recognizes foundational discoveries about regulatory T cells and the FOXP3 gene that redefined immune tolerance and opened avenues to treat autoimmune disease, enable transplantation, and advance immuno-oncology. ISB celebrates Dr. Brunkow’s leadership and collaborative science.
The pioneering work of Mary Brunkow and Fred Ramsdell began with a mysterious mutant mouse known as “scurfy,” leading them to identify the FOXP3 gene and unlock how regulatory T cells prevent autoimmune disease — discoveries that now point to new treatments in cancer and autoimmunity.
Researchers at ISB have developed personalized models to predict C. diff colonization risk and test targeted probiotics. This approach could prevent infection before it starts and paves the way for precision microbiome therapies tailored to individual gut ecosystems.
ISB scientists have developed a simple, low-cost method to measure the total amount of bacteria in the gut using existing sequencing data. This breakthrough could speed up microbiome research and unlock new insights into health and disease.
ISB’s Gibbons Lab developed a breakthrough method that analyzes food-derived DNA in fecal metagenomes, allowing for data-driven diet tracking without the need for burdensome questionnaires.
Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.
ISB researchers have developed a novel way to simulate personalized, microbiome-mediated responses to diet. They use a microbial community-scale metabolic modeling (MCMM) approach to predict individual-specific short-chain fatty acid production rates in response to different dietary, prebiotic, and probiotic inputs.
ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.